Aller au contenu principal
Accès ouvert déclaré 2023 article

The CryoPop study: Screening for high‐grade cervical dysplasia in Karnataka, India

2Citations signalées, ce qui n’est pas une note de qualité
7Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : us, in. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

OBJECTIVE: To describe our experience of screening with visual inspection with acetic acid (VIA) and colposcopy to identify women with high-grade precancerous cervical lesions who were candidates for cryotherapy. Women were screened to determine eligibility for a clinical trial testing the safety and efficacy of a new, simple and inexpensive cryotherapy device (CryoPop®) targeted for use in low and middle-income countries (LMICs). DESIGN: Prospective cohort study. SETTING: Primary and urban health centres in Belagavi, Hubballi and Vijayapur, India. POPULATION: Women in the age-group 30-49 years, premenopausal, with no prior hysterectomy and no known HIV infection were eligible for screening. METHODS: Visual inspection with acetic acid was performed on eligible women following informed consent. VIA-positive women were referred for colposcopy and biopsy. Biopsies were read by two pathologists independently, with a third pathologist acting as tie-breaker if needed. MAIN OUTCOME MEASURES: The primary outcome measures were the number/proportion of women screening positive by VIA and the number/proportion of those women screening VIA-positive found to have high-grade cervical lesions on biopsy (cervical intraepithelial neoplasia 2/3 [CIN 2/3]). Demographic variables were compared between women who screened VIA-positive and those who screened VIA-negative; a separate comparison of demographic and limited reproductive variables was performed between women who had CIN 2/3 on biopsy and those without CIN 2/3 on biopsy. Chi-square or Fisher's exact tests for categorical data and t-tests or analysis of variance for numeric data were used with all tests two-sided and performed at an alpha 0.05 level of statistical significance. RESULTS: A total of 9130 women were screened with VIA between 4 July 2020 and 31 March 2021. The mean age of all women screened was 37 years (standard deviation = 5.6 years) with 6073 of the women (66.5%) in the 30-39 year range. Only 1% of women reported prior cervical cancer screening. A total of 501 women (5.5%) were VIA-positive; of these, 401 women underwent colposcopy. Of those who had colposcopy, 17 (4.2%) had high-grade lesions on biopsy, an additional 164 (40.9%) had low-grade cervical lesions on biopsy or endocervical curettage and one woman (0.2%) was found to have invasive cancer. VIA-positive women were younger and had higher levels of education and income; however, women who were VIA-positive and found to have CIN 2/3 were older, were more likely to be housewives and had higher household income than those without CIN 2/3. CONCLUSION: Despite the COVID-19 pandemic, over 9100 women were screened with VIA for precancerous lesions. However, only 17 (4.2%) were found to have biopsy-proven high-grade cervical lesions, underscoring the subjective performance of VIA as a screening method. Given that this is significantly lower than rates reported in the literature, it is possible that the prevalence of high-grade lesions in this population was impacted by screening a younger and more rural population. This study demonstrates that screening is feasible in an organised fashion and can be scaled up rapidly. However, while inexpensive and allowing for same-day treatment, VIA may be too subjective and have insufficient accuracy clearly to identify lesions requiring treatment, particularly in low-prevalence and low-risk populations, calling into question its overall cost-effectiveness.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The CryoPop study: Screening for high‐grade cervical dysplasia in Karnataka, India
Date Crossref
01/11/2023
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Johns Hopkins University Jhpiego pays non établi dans la notice
    Université ou école supérieure
  • Johns Hopkins Medicine pays non établi dans la notice
    Établissement de santé
  • Jawaharlal Nehru Medical College Department of Community Medicine pays non établi dans la notice
    Université ou école supérieure
  • Jhpiego pays non établi dans la notice
    Organisation à but non lucratif
  • Karnataka Institute of Medical Sciences pays non établi dans la notice
    Établissement de santé
  • Shri BM Patil Medical College pays non établi dans la notice
    Université ou école supérieure
  • Thomas Jefferson University pays non établi dans la notice
    Université ou école supérieure
  • Research Institute Hubballi India Karnataka Cancer Therapy &amp pays non établi dans la notice
    Structure de recherche
  • BLDE (Deemed‐to‐be‐University) Shri B M Patil Medical College Hospital and Research Centre Vijayapura India pays non établi dans la notice
    Université ou école supérieure
  • BLDE (Deemed-to-be-University) Shri B M Patil Medical College Hospital and Research Centre pays non établi dans la notice
    Université ou école supérieure

Jhpiego — Johns Hopkins University, Johns Hopkins Medicine et Department of Community Medicine — Jawaharlal Nehru Medical College, avec 7 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Cervical Cancer and HPV ResearchWomen's cancer prevention and managementReproductive tract infections research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.